[{"id":"e0b289b2-400b-4353-a2bf-4b76dfb7f062","acronym":"","url":"https://clinicaltrials.gov/study/NCT06098898","created_at":"2023-10-25T19:13:53.207Z","updated_at":"2024-07-02T16:35:31.813Z","phase":"Phase 1","brief_title":"Safety and Efficacy of NK510 to Treat Gastric Cancer","source_id_and_acronym":"NCT06098898","lead_sponsor":"Base Therapeutics (Shanghai) Co., Ltd.","biomarkers":" HER-2 • PD-L1","pipe":" | ","alterations":" PD-L1 expression • HER-2 expression • HER-2 positive + PD-L1 expression • PD-L1 expression + HER-2 expression","tags":["HER-2 • PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • HER-2 expression • HER-2 positive + PD-L1 expression • PD-L1 expression + HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Tecentriq (atezolizumab) • Tevimbra (tislelizumab-jsgr)"],"overall_status":"Enrolling by invitation","enrollment":" Enrollment 9","initiation":"Initiation: 11/01/2023","start_date":" 11/01/2023","primary_txt":" Primary completion: 11/01/2024","primary_completion_date":" 11/01/2024","study_txt":" Completion: 11/01/2024","study_completion_date":" 11/01/2024","last_update_posted":"2023-10-25"}]